Display options
Cite
Tantry US, Schror K, Navarese EP, et al. Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. J Exp Pharmacol. 2021;13:957-970doi: 10.2147/JEP.S330776.
Tantry, U. S., Schror, K., Navarese, E. P., Jeong, Y. H., Kubica, J., Bliden, K. P., & Gurbel, P. A. (2021). Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. Journal of experimental pharmacology, 13957-970. https://doi.org/10.2147/JEP.S330776
Tantry, Udaya S, et al. "Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent." Journal of experimental pharmacology vol. 13 (2021): 957-970. doi: https://doi.org/10.2147/JEP.S330776
Tantry US, Schror K, Navarese EP, Jeong YH, Kubica J, Bliden KP, Gurbel PA. Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. J Exp Pharmacol. 2021 Dec 07;13:957-970. doi: 10.2147/JEP.S330776. eCollection 2021. PMID: 34908882; PMCID: PMC8665864.
Copy Download .nbib Format: NLM
Share it on

J Exp Pharmacol. 2021 Dec 07;13:957-970. doi: 10.2147/JEP.S330776. eCollection 2021.

Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.

Journal of experimental pharmacology

Udaya S Tantry, Karsten Schror, Eliano Pio Navarese, Young-Hoon Jeong, Jacek Kubica, Kevin P Bliden, Paul A Gurbel

Affiliations

  1. Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD, USA.
  2. Department of Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany.
  3. Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland.
  4. Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea.

PMID: 34908882 PMCID: PMC8665864 DOI: 10.2147/JEP.S330776

Abstract

INTRODUCTION: Pharmacologic therapy options for COVID-19 should include antiviral, anti-inflammatory, and anticoagulant agents. With the limited effectiveness, currently available virus-directed therapies may have a substantial impact on global health due to continued reports of mutant variants affecting repeated waves of COVID-19 around the world.

METHODS: We searched articles pertaining to aspirin, COVID-19, acute lung injury and pharmacology in PubMed and provide a comprehensive appraisal of potential use of aspirin in the management of patients with COVID-19. The scope of this article is to provide an overview of the rationale and currently available clinical evidence that supports aspirin as an effective therapeutic option in COVID-19.

RESULTS: Experimental and clinical evidence are available for the potential use of aspirin in patients with COVID-19.

DISCUSSION: Aspirin targets the intracellular signaling pathway that is essential for viral replication, and resultant inflammatory responses, hypercoagulability, and platelet activation. With these multiple benefits, aspirin can be a credible adjunctive therapeutic option for the treatment of COVID-19. In addition, inhaled formulation with its rapid effects may enhance direct delivery to the lung, which is the key organ damaged in COVID-19 during the critical initial course of the disease, whereas the 150-325 mg/day can be used for long-term treatment to prevent thrombotic event occurrences. Being economical and widely available, aspirin can be exploited globally, particularly in underserved communities and remote areas of the world to combat the ongoing COVID-19 pandemic.

© 2021 Tantry et al.

Keywords: COVID-19; acetyl salicylic acid; acute respiratory syndrome; inflammation; lungs; platelets

Conflict of interest statement

Dr Tantry received Honoraria from UpToDate and AggreGuide. Dr Gurbel has received consulting fees and/or honoraria from Bayer, Otitopic, Janssen, UpToDate, US WorldMeds, Hikari Dx, and Medicure; insti

References

  1. Thromb Haemost. 2017 Aug 30;117(9):1798-1807 - PubMed
  2. Prog Cardiovasc Dis. 2009 Sep-Oct;52(2):141-52 - PubMed
  3. J Exp Med. 2004 Jul 5;200(1):69-78 - PubMed
  4. Circulation. 2002 Apr 9;105(14):1650-5 - PubMed
  5. Thromb Haemost. 2007 Jan;97(1):88-98 - PubMed
  6. Crit Care. 2015 Oct 23;19:374 - PubMed
  7. Pharmacol Res. 2016 May;107:415-425 - PubMed
  8. Circulation. 2020 Jul 28;142(4):315-317 - PubMed
  9. Vasc Med. 2021 Dec;26(6):626-632 - PubMed
  10. Antioxidants (Basel). 2020 May 15;9(5): - PubMed
  11. Emerg Microbes Infect. 2018 Mar 7;7(1):21 - PubMed
  12. Crit Care Med. 2011 Nov;39(11):2393-400 - PubMed
  13. J Thromb Thrombolysis. 2021 Feb;51(2):260-264 - PubMed
  14. J Med Virol. 2021 Sep;93(9):5390-5395 - PubMed
  15. J Thromb Haemost. 2014 Nov;12(11):1776-87 - PubMed
  16. Biochem J. 1989 Apr 15;259(2):315-24 - PubMed
  17. Biochem Pharmacol. 2020 Aug;178:114094 - PubMed
  18. Shock. 2017 Jan;47(1):13-21 - PubMed
  19. Nature. 1998 Nov 5;396(6706):77-80 - PubMed
  20. PLoS Pathog. 2017 Mar 29;13(3):e1006286 - PubMed
  21. Cell Microbiol. 2007 Jul;9(7):1683-94 - PubMed
  22. J Cell Mol Med. 2021 Jan;25(2):1263-1273 - PubMed
  23. N Engl J Med. 2020 Jul 9;383(2):120-128 - PubMed
  24. Crit Care. 2015 Mar 23;19:109 - PubMed
  25. Blood. 2014 Oct 23;124(17):2625-34 - PubMed
  26. Cells. 2021 Jan 14;10(1): - PubMed
  27. Cell. 2020 Apr 16;181(2):281-292.e6 - PubMed
  28. Crit Care Med. 2017 Nov;45(11):1871-1879 - PubMed
  29. Sci Rep. 2015 Jan 20;5:7896 - PubMed
  30. Nature. 2017 Apr 6;544(7648):105-109 - PubMed
  31. Cancer Prev Res (Phila). 2016 Nov;9(11):855-865 - PubMed
  32. Blood Adv. 2021 Feb 9;5(3):872-888 - PubMed
  33. Am J Respir Crit Care Med. 2020 Dec 1;202(11):1509-1519 - PubMed
  34. J Thromb Haemost. 2015 May;13(5):795-801 - PubMed
  35. Science. 2009 Aug 14;325(5942):834-40 - PubMed
  36. Trends Immunol. 2020 Dec;41(12):1100-1115 - PubMed
  37. Br J Pharmacol. 2004 Sep;143(1):159-65 - PubMed
  38. Blood. 2020 Jun 4;135(23):2033-2040 - PubMed
  39. Pharmaceutics. 2015 Aug 03;7(3):188-98 - PubMed
  40. Am J Physiol Lung Cell Mol Physiol. 2015 Nov 1;309(9):L915-23 - PubMed
  41. Mucosal Immunol. 2013 Mar;6(2):256-66 - PubMed
  42. Biomedicines. 2020 Jul 21;8(7): - PubMed
  43. J Diabetes Complications. 2016 Sep-Oct;30(7):1365-70 - PubMed
  44. Thromb Haemost. 2014 Aug;112(2):323-31 - PubMed
  45. FEBS J. 2021 Sep;288(17):5179-5189 - PubMed
  46. Intensive Care Med. 2020 Jun;46(6):1089-1098 - PubMed
  47. Drugs. 2020 Sep;80(14):1383-1396 - PubMed
  48. Eur Heart J. 2017 Jun 1;38(21):1687-1689 - PubMed
  49. Clin Cardiol. 2017 Dec;40(12):1352-1356 - PubMed
  50. Front Immunol. 2020 Dec 10;11:598444 - PubMed
  51. Crit Care Med. 2013 Feb;41(2):399-404 - PubMed
  52. J Hematol Oncol. 2020 Sep 4;13(1):120 - PubMed
  53. Circulation. 2020 Sep 29;142(13):1305-1307 - PubMed
  54. Influenza Other Respir Viruses. 2017 Jan;11(1):85-92 - PubMed
  55. Arterioscler Thromb Vasc Biol. 2020 Aug;40(8):1818-1829 - PubMed
  56. N Engl J Med. 1988 Sep 22;319(12):797 - PubMed
  57. Front Pharmacol. 2020 May 19;11:738 - PubMed
  58. Blood. 2007 Mar 15;109(6):2285-92 - PubMed
  59. Anesth Analg. 2021 Apr 1;132(4):930-941 - PubMed
  60. J Biol Chem. 2007 Mar 30;282(13):9323-9334 - PubMed
  61. PLoS One. 2021 Feb 11;16(2):e0246825 - PubMed
  62. Crit Care Med. 2012 Jun;40(6):1761-7 - PubMed
  63. J Thromb Thrombolysis. 2020 Nov;50(4):790-794 - PubMed
  64. Medicine (Baltimore). 2021 Feb 12;100(6):e24544 - PubMed
  65. Crit Care. 2013 Jan 08;17(1):402 - PubMed
  66. Front Microbiol. 2017 Nov 02;8:2130 - PubMed
  67. J Pharmacol Exp Ther. 2013 Jun;345(3):430-7 - PubMed
  68. Crit Care Med. 2011 Jun;39(6):1343-50 - PubMed
  69. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620943293 - PubMed
  70. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973 - PubMed
  71. Chest. 2011 Feb;139(2):289-295 - PubMed
  72. Am J Surg Pathol. 2021 May 1;45(5):587-603 - PubMed
  73. Am J Hematol. 2021 Apr 1;96(4):471-479 - PubMed
  74. Science. 1995 Dec 22;270(5244):2017-9 - PubMed
  75. Blood Coagul Fibrinolysis. 2007 Dec;18(8):713-8 - PubMed
  76. Int J Infect Dis. 2021 Jul;108:6-12 - PubMed
  77. Crit Care Med. 2015 Apr;43(4):801-7 - PubMed
  78. Circulation. 2008 Oct 21;118(17):1705-12 - PubMed
  79. J Pathol. 2006 Nov;210(3):288-97 - PubMed
  80. Viruses. 2021 Mar 01;13(3): - PubMed
  81. J Clin Invest. 2006 Dec;116(12):3211-9 - PubMed
  82. Diabetes Care. 2012 Feb;35(2):404-8 - PubMed

Publication Types